Article

Anaerobic bacteria infection in cystic fibrosis airway disease.

Department of Cellular and Molecular Biology and Pathology Luigi Califano, Medical School, Federico II University, Naples, Italy.
The New Microbiologica: official journal of the Italian Society for Medical Virology (SIVIM) (Impact Factor: 1.6). 07/2010; 33(3):185-94.
Source: PubMed

ABSTRACT Depletion of the periciliary liquid in "Cystic Fibrosis" airway disease results in reduced mucociliary transport, persistent mucus hypersecretion and consequently increased height of the luminal mucus layer, so hypoxic gradients in the mucus plugs are developed. Because of anaerobic lung zones, it is highly probable that anaerobic bacteria not detected by routine bacteriologic culture methods also reside within the mucus. Notwithstanding this evidence, microbiology laboratories working in the cystic fibrosis field do not generally use strict anaerobic bacteriologic cultures to determine the presence of anaerobic bacteria in the Cystic Fibrosis lung. The aim of this review is to focus on the published data regarding the finding of anaerobic bacteria in cystic fibrosis airway disease. Therefore, microbiology, diagnosis, antimicrobial susceptibility and possible impact on clinical management of anaerobic bacteria lung infection in cystic fibrosis are described.

Full-text

Available from: Maria Rosaria Catania, May 04, 2015
0 Followers
 · 
244 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Cystic fibrosis (CF) lung is a niche colonised by a diverse group of organisms, with a more limited number of species including P. aeruginosa dominating in adult patients. Whether all members of this microbial community play a direct or indirect role in pulmonary decline has yet to be fully elucidated, but investigations of their interactions with both co-colonising species and with host cells are beginning to shed light on their virulence potential. It is also emerging that some microbial species within this community adapt as chronic infection is established to survive the hostile environment of the lung, to minimise host clearance and to resist therapeutic intervention. Interactions of clearly defined CF pathogens with the host have been recently reviewed (Callaghan and McClean, 2012). This review highlights the recent developments in CF microbiology focussing on the cooperative, competitive and adaptive interactions of established and emerging pathogens in the lung microbiome.
    Environmental Microbiology 05/2014; 17(1). DOI:10.1111/1462-2920.12504 · 6.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: The cystic fibrosis (CF) airway mucus is an ideal niche in which many bacteria can develop antibiotic- and phagocyte-resistance in unique structures known as "mode II biofilms" where bacteria are embedded within the mucus, yet unattached to airway epithelial cells. Pseudomonas aeruginosa is the dominant CF pathogen, yet herein the authors provide burgeoning evidence that obligate anaerobic bacteria (e.g., Prevotella) actually thrive within the CF mucus, a paradigmatic shift that chronic CF is an "aerobic" disease. Interestingly, CF organisms repress virulence factor production (e.g., P. aeruginosa) while others (e.g., S. aureus) increase them under anaerobic conditions. AREAS COVERED: The authors shed additional light on (i) the anoxic nature of the CF airway mucus, (ii) the relative commonality of anaerobic bacteria isolated from CF sputum, (iii) virulence factor production and cross-talk between obligate anaerobes and P. aeruginosa relative to disease progression/remission, (iv) the role of mucoidy in CF, and (v) the role of nitrosative stress in activation of bacteriophage and pyocins within biofilms. EXPERT OPINION: The authors conclude with insight as to how we might treat some CF bacteria during mode II biofilm infections that utilizes a metabolite of bacterial anaerobic respiration and an aerobic oxidation product of airway-generated NO, acidified NO(2)(-).
    Expert Opinion on Therapeutic Targets 07/2012; 16(9):859-73. DOI:10.1517/14728222.2012.708025 · 4.90 Impact Factor